ATC Group: A03FA02 Cisapride

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A03FA02 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A03 Drugs for functional gastrointestinal disorders
3 A03F Propulsives
4 A03FA Propulsives
5 A03FA02 Cisapride

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 30 mg
RECTAL - Rectal 30 mg

Active ingredients in A03FA02

Active Ingredient Description
Cisapride

Cisapride is a substituted piperidinyl benzamide prokinetic agent. Cisapride facilitates release of acetylcholine from the myenteric plexus, resulting in increased gastrointestinal motility. In addition, cisapride has been found to act as a serotonin agonist, stimulating type 4 receptors, and a serotonin 5-HT3 receptor antagonist.

Medicines in this ATC group

Mexico (MX)

Poland (PL)

South Africa (ZA)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.